The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2-year study on 129 eyes.
OBJECTIVE
To evaluate the effect of prostaglandin analogues on the central corneal thickness (CCT) of patients with chronic open-angle glaucoma (COAG).


METHODS
One hundred and twenty-nine eyes were included in this study. Of these, 108 were treated with prostaglandin analogues (latanoprost, travoprost and bimatoprost), while 21 eyes treated with β-blockers were used as controls. CCT was measured before treatment and at 3-month intervals.


RESULTS
A slight but significant increase in CCT was recorded in the bimatoprost and latanoprost groups. Treatment with bimatoprost produced a constant increase (1.85-8.83 μm) in CCT at all time-points of the study. The CCT rise found in the latanoprost group was significant for the first year. Treatment with travoprost did not affect CCT.


CONCLUSIONS
The possibility of corneal thickening under prolonged, local prostaglandin treatment should be investigated further. However, in clinical practice, CCT changes may sometimes influence intraocular pressure measurements significantly.
Bafa
Maria
M
Ophthalmology Department, Thriassio General Hospital, Athens, Greece. mbf90@otenet.gr
Georgopoulos
Gerasimos
G
Mihas
Constantinos
C
Stavrakas
Panagiotis
P
Papaconstantinou
Dimitrios
D
Vergados
Ioannis
I
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000368:Aged; D000577:Amides / Q000008:administration & dosage / Q000009:adverse effects; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003315:Cornea / Q000000981:diagnostic imaging* / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D011465:Prostaglandins, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D000069557:Travoprost; D014463:Ultrasonography
D000319:Adrenergic beta-Antagonists; D000577:Amides; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost